Brief: Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate Ocular
11/07/2025 01:05
July 11 (Reuters) - Cambium Bio Ltd CMB.AX: CLEARS US FDA REGULATORY HURDLES TO COMMENCE PHASE 3 DOSING FOR ELATE OCULAR Further company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cambium Bio
See all newsAustralia's Cambium Bio hits near three-month high on share placement at premium
Brief: Cambium Bio Appoints Olga Smejkalova As Company Secretary
Australia's Cambium Bio gains after premium share placement
Brief: Cambium Bio Raises A$1 MLN At A$0.48 Per Share
Brief: Cambium Bio Receives A$2.4 Million Investment From Zheng Yang Biomedical Technology